In previous studies bryostatin has been shown to cause dosedependent stimulatory or inhibitory effects on colony formation in acute myeloid leukemias. In this study we investigated the inhibitory effect of high dose bryostatin-1 (bryo-1) on normal human bone marrow mononuclear cells (BMNC) colonyforming capacity. Preculturing BMNC for 24 h with 250 nM bryo-1 reduced colony formation by 66 ± 11% whereas this treatment did not reduce clonogenic capacity of highly purified CD34 
Introduction
Bryostatins are a group of natural compounds isolated from the marine animal Bugula neritina. 1 Bryostatins support the in vitro growth of human hematopoietic progenitor cells in a dose-dependent manner at an optimal concentration between 1 and 10 nM. 2 In the absence of accessory cells bryostatin-1 does not stimulate clonogenic growth of purified human hematopoietic progenitor cells 3 and the stimulatory effect appears to be mediated through bryostatin-induced release of cytokines from accessory cells such as interleukin-3 and GM-CSF. 4 Previously, we and others found that continuous bryostatin exposure during colony-forming cultures strongly inhibits leukemic cell colony formation, including HL60 cells. [5] [6] [7] [8] This differential effect exerted by bryostatins on normal and leukemic progenitor cell growth suggests that these agents could be of potential clinical use as antileukemic agents.
However, scheduling studies with 0.1-10 nM bryostatin in freshly obtained patient acute myeloid leukemia (AML) samples showed erratic, unpredictable growth responses rangCorrespondence: AM Dräger; Fax: 31 20 4442601 Received 29 April 1998; accepted 30 September 1998 ing from inhibition to frank stimulation. 9 In addition, we found that higher concentrations of bryostatin (such as 250 nM) exerted a differential effect on normal and leukemic clonogenicity: normal bone marrow cell colony formation was consistently inhibited, HL60 leukemic cell clonogenicity was hardly inhibited, and freshly obtained AML patient samples were commonly stimulated in their clonogenic growth. 9 Thus, bryostatins exhibit a complex relationship between dose, dose scheduling, and effect. The underlying mechanisms of these remarkable dose-dependent differential effects exerted by bryostatin on normal and leukemic hematopoiesis might give more insight into factors involved in differential hematopoietic regulation. Therefore, in this study we investigated the inhibitory effect of 250 nM bryostatin-1 on normal human bone marrow clonogenicity and explored the role of accessory cells therein.
Materials and methods

Reagents
Bryostatin-1 (bryo-1) was generously provided by Dr GR Petitt (Arizona State University, Tempe, AZ, USA). A stock solution of 10 −4 M bryo-1 was made in dimethylsulfoxide and kept at −30°C. Before use the stock solution was diluted with culture medium (see below) to a final concentration of 250 nM.
Polyclonal neutralizing anti-human antibodies against IL4, IL8, IL10, interferon (IFN)␥, MIP1␣, and transforming growth factor (TGF␤) were purchased from PeproTech (Rocky Hill, NJ, USA). A polyclonal neutralizing anti-human tumor necrosis factor alpha (TNF␣) antibody was purchased from Genzyme (Cambridge, MA, USA). All antibodies were used at a concentration calculated to neutralize at least 5 ng/ml of the designated cytokine. Recombinant human TNF␣ (specific activity 10 8 U/mg) was purchased from Boehringer Mannheim (Almere, The Netherlands).
Mouse anti-human CD2 and mouse anti-human CD14 monoclonal antibodies were obtained from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (Amsterdam, The Netherlands). Goat anti-mouse-labelled Biomag beads were obtained from PerSeptive Diagnostics (Cambridge, MA, USA).
Mouse anti-human CD2 FITC and CD14 FITC and irrelevant isotypic control antibodies were obtained from Dako (Glostrup, Denmark). Mouse anti-human CD34 PE antibodies, recognizing the HPCA-2 antigen, were obtained from Becton Dickinson (BD, San Jose, CA, USA).
Cells and culture medium
Heparinized bone marrow samples were aspirated after informed consent from healthy volunteers or hematologically normal patients undergoing cardiac bypass surgery. Specimens were diluted 1:10 in Hank's balanced salt solution (HBSS) containing 0.1% bovine serum albumin (BSA: Organon Teknika, Boxtel, The Netherlands). The bone marrow mono-nuclear cell (BMNC) fraction was recovered by Ficoll (Nycomed Pharma, Oslo, Norway) density gradient (␦ = 1.077g/cm 3 ) centrifugation and washed twice in HBSS/BSA.
Culture medium consisted of RPMI-1640 medium with Lglutamine supplemented with 100 IU/ml penicillin, 100 g/ml streptomycin, and 20% heat-inactivated fetal calf serum (FCS). Cell counts were obtained using a Neubauer cell chamber and cell viability was assessed by the trypan blue dye exclusion test. Cell cultures were kept in a 5% CO 2 fully humidified atmosphere at 37°C.
CD2 and CD14 depletion
Following density gradient centrifugation, remaining erythrocytes in the BMNC fraction were lysed by 5 min exposure on thawing ice to a lysing solution containing 155 mM NH 4 Cl, 10 mM KHCO 3 , and 0.1 mM EDTA. After two washes in HBSS/BSA, 20 × 10 6 BMNC were resuspended in 1 ml RPMI supplemented with 10% FCS on thawing ice. To these cultures mouse anti-human CD2 or mouse anti-human CD14 monoclonal antibodies were added in a final dilution of 1:100. After 30 min on thawing ice, 40 l of thrice washed Biomag beads per 10 6 cells were added for another 30 min while stirring for a short while every 5 min. In three successive rounds against a magnet, labelled cells were depleted. After two washes, the fractions obtained were seeded at 1 × 10 6 cells in 1 ml culture medium. Efficacy of depletion was analyzed by FACScan flowcytometry (BD).
CD34-positive and -negative cell selection
Following density gradient separation, CD34-positive cells were isolated using the MiniMACS magnetic separation system (Miltenyi Biotech, Bergisch Gladbach, Germany). Briefly, 10 8 BMNC were suspended in 300 l ice-cold phosphatebuffered saline containing 0.5% BSA and 5 mM EDTA (buffer medium). To saturate nonspecific binding sites, cells were incubated for 10 min with 100 l human IgG. Subsequently, cells were incubated for 15 min on thawing ice with 100 l of mouse anti-human CD34 monoclonal antibodies (Qbend/10; BD). After a careful wash, the cell pellet was resuspended in 400 l buffer after which cells were incubated for 15 min at 8°C with 100 l colloidal superparamagnetic MACS microbeads coated with anti-murine Ig. After washing, cells were resuspended in 500 l buffer and applied to a magnetic separation column. The effluent cells from this separation step were collected as the CD34 − cell fraction. Retained cells were eluted from the column with buffer medium and subjected to a second magnetic separation step using a second column. The cells eluted from this column made up the CD34 + cell fraction. After two consecutive passages over two separation columns, CD34
+ cell purity was 93.5 ± 0.8% (mean ± s.e.m.; n = 9) as determined by FACScan flowcytometry.
Preincubation cultures
Crude BMNC as well as CD2
+ and CD14 Following preincubation cultures, all cells were harvested, washed twice in HBSS/BSA, resuspended in fresh Iscove's medium, counted, and plated in CFU medium (see below). The viability of crude or fractionated cells as determined by trypan blue dye exclusion was above 80% after incubation with 250 nM bryo-1 for 24 h in all experiments described.
Supernatants
Supernatants were sampled from all cultures preincubated for 24 h in the absence or presence of bryo-1 and stored at −30°C before use in further experiments.
Preparation of conditioned medium (CM)
To prepare bryo-1 CM, 20 × 10 6 BMNC were cultured in 5 ml of culture medium with and without 250 nM bryo-1. Both supernatants were harvested after 24 h and stored frozen at −30°C until further use. Before use, CM was diluted 1:1 with fresh culture medium. A similar procedure was followed for TNF␣ CM, using 100 U/ml TNF␣.
TNF␣ assay
TNF␣ concentrations were measured using the Pelikine compact human TNF␣ ELISA kit (Central Laboratory of the Netherlands Red Cross Blood Transfusion Service) according to the manufacturer's instructions. The sensitivity of this assay is у3 pg/ml.
Clonogenic assays
Except for CD34
+ cells, all cell fractions were suspended at 5 × 10 4 viable cells in 1 ml Methocult GF H4434 CFU medium (StemCell Technologies, Vancouver, BC, Canada). According to the manufacturer, the medium contains 50 ng/ml rhSCF, 10 ng/ml rhGM-CSF, 10 ng/ml rhIL3 and 3 ng/ml rhEPO. CD34 + cells were suspended at 2 × 10 3 cells in 1 ml of this CFU medium. Duplicate cultures were established within a 24-well cluster plate (Costar 3524), adding 250 l CFU suspension per well. The outer 16 wells were filled with phosphate-buffered saline to prevent evaporation.
After 10-12 days of incubation in a fully humidified atmosphere in 5% CO 2 at 37°C, clonogenic capacity was determined using an inverted microscope. CFU-GM were defined as the total number of granulocyte-macrophage colonies (aggregates Ͼ40 cells) and clusters (groups of 8-40 cells). Mean values of the duplicate cultures were used for data calculation.
Results presented are the mean value ± standard error of the mean (s.e.m.) of data from all experiments performed (numbers shown in the legends).
Figure 1
Colony formation after bryostatin-1 treatment in crude bone marrow mononuclear cells and highly purified CD34
+ bone marrow cells. Crude bone marrow mononuclear cells (BMNC) (open bar, n = 6) and purified CD34
+ bone marrow cells (closed bar, n = 6) were precultured for 24 h in the presence of 250 nM bryostatin-1, washed twice, and plated in a CFU assay. Results are presented as the mean percentage CFU-GM ± s.e.m. compared to control cultures preincubated without bryo-1.
Results
Role of accessory cells in bryostatin-induced inhibition of clonogenic capacity
Preincubation of BMNC with 250 nM bryo-1 for 24 h markedly reduced BMNC CFU-GM as compared to untreated control BMNC (Figure 1 ). On the other hand, purified CD34
+ cells preincubated with bryo-1 showed no reduction in the number of CFU-GM when compared to untreated CD34 + cells ( Figure 1 ). In this situation a low concentration of cells has been used, assuming that the uptake/binding of bryo-1 was at least as large and probably higher than that in the CD34 cells of the crude bone marrow. The observed differential effect of bryo-1 suggests a role for accessory cells in inhibition of CFU-GM after pretreatment. This finding was confirmed by the following experiments: (1) CD34
+ cells when seeded in a transwell culture with the culture chamber insert containing CD34 − cells, showed reduced clonogenicity upon bryo-1 exposure (Table 1, 
row 4). Again CD34
+ cell clonogenicity was not affected by bryo-1 when CD34 − cells were absent (Table 1 , row 2). (2) When CD34-negative accessory cells were preincubated for 24 h with bryo-1 and after extensive washing co- + cells for 24 h, subsequent CFU-GM formation after thorough washing was 60.3 ± 4.3% (n = 10, part of Figure 7 ) compared to CFU-GM formation by CD34
+ cells cultured in control CM. These experiments strongly suggest the presence of soluble factor(s) secreted by the CD34-negative cell fraction in response to bryo-1 and necessary for the observed colony inhibition.
Effects of neutralizing antibodies during the preincubation period
To define such inhibitory factor(s), crude BMNC samples were cultured in the presence of neutralizing antibodies against various cytokines known to be able to inhibit clonogenic hematopoietic progenitor cell growth. 10, 11 As can be seen in Figure 2 , the addition of anti-IL4, anti-IL8, anti-IFN␥, or anti-TGF␤ to bryo-1-stimulated precultures had no effect on subsequent CFU-GM formation. Addition of anti-IL10 only slightly reversed the inhibitory effect of bryo-1 on CFU-GM. In contrast, the addition of anti-TNF␣ to preincubation cultures completely abrogated bryo-1-induced inhibition of CFU-GM.
Based on these experiments it may be concluded that TNF␣ has an etiological role in determining the inhibitory effects of bryo-1 on hematopoietic progenitor cell growth.
Effects of CD2 and CD14 depletion prior to bryostatin priming
To further characterize the role of accessory cells in the production of the inhibitory factor, the preincubation experiments as described above were repeated with either CD2 (Tlymphocyte) or CD14 (monocyte)-depleted BMNC fractions. Following depletion, the CD2-depleted BMNC fraction con-
Figure 2
Colony formation after bryostatin-1 treatment in bone marrow mononuclear cells: effects of cytokine neutralization by antibodies. Crude BMNC were precultured for 24 h with 250 nM bryo-1 in the presence of several cytokine neutralizing antibodies and plated in a CFU assay. The number of experiments performed is stated in parentheses beside each cytokine. The percentage CFU-GM compared to untreated control cultures is shown. CFU-GM numbers of untreated control was 190 ± 54 (12.5 × 10 3 plated).
tained 0.2 ± 0.2% residual CD2 + cells compared to an initial percentage of 19.9 ± 4.3% (mean ± s.e.m.; n = 5). The percentage of CD14
+ cells was reduced from 7.0 ± 0.9% to 0.3 ±0.2% (mean ± s.e.m.; n = 5).
As can be seen in Figure 3 , CD14 + but not CD2 + cell depletion largely abrogated the clonogenic inhibition induced by bryo-1. The residual slight inhibition (about 12%) might originate from the residual CD14 + cells or from other cell fractions. In control experiments an equal amount of purified CD14
+ cells (compared to the crude fraction) was plated in the upper transwell during the preincubation period. The viability of CD14 + cells in the presence of 250 nM bryo-1 remained the same as compared to CD14
+ cells cultured in the absence of bryo-1 (Ͼ80%), showing that the dose used is not toxic for monocytes. Under these conditions only a 23% inhibition (n = 3, data not shown) of CFU-GM formation was found compared to 69% as shown in Figure 3 for the crude fraction, indicating that the presence of CD14
+ cells is necessary but not sufficient to produce the inhibitory effect. In the presence of anti-TNF␣ bryo-1-induced inhibition of CFU-GM was undone in all BMNC fractions (Figure 3) .
These experiments indicate that TNF␣ production by monocytes upon bryo-1 stimulation is a necessary but not the sole step for bryo-1-induced inhibition of clonogenic cell growth. In the whole process there is a role for non-CD14
+ accessory cells.
Role of TNF␣ in inhibition of myelopoiesis
To further characterize this role of TNF␣, TNF␣ concentrations in culture supernatants were determined. In nine out of 13 bryo-1-stimulated BMNC cultures considerable increases in the TNF␣ levels over baseline values were measured (Figure 4a ). The same was true for bryo-1-treated cultures after depletion of CD2 cells whereas CD14-depleted BMNC cultures contained no or scarcely detectable TNF␣ with or
Figure 3
Colony formation after bryostatin-1 treatment in T-lymphocyte and monocyte-depleted mononuclear bone marrow cells: effect of anti-TNF␣. Crude BMNC (open bars; n = 9), CD2
+ celldepleted BMNC (hatched bars; n = 8), and CD14
+ cell-depleted BMNC (black bars; n = 7) were stimulated for 24 h with 250 nM bryo-1 in the presence or absence of anti-TNF␣ antibody, washed twice, and plated in a CFU assay. Results are presented as the mean percentage CFU-GM ± s.e.m. compared to untreated control cultures. CFU-GM numbers per 12.5 × 10 3 plated cells amounted to: 167 ± 46 crude BMNC; 188 ± 59 CD2-depleted BMNC, 120 ± 19 CD14-depleted BMNC. Sole pretreatment of cells with anti-TNF␣ for 24 h had no effect: clonogenicity was 94.9 ± 14% (mean ± s.e.m.; n = 16) as compared to untreated control samples.
without bryo-1 stimulation (Figure 4c ). Supernatants from BMNC cultures with bryo-1 in the presence of anti-TNF␣ showed no detectable TNF␣ levels indicating that induced TNF␣, if present, was completely neutralized (Figure 4a-c) .
Supernatants of bryo-1-stimulated CD34
+ cells contained no detectable TNF␣ (data not shown).
Secondly, crude BMNC as well as purified CD34 + cells were pretreated with TNF␣ in concentrations ranging from 0 to 16 000 pg/ml covering all concentrations as found in Figure 4 in supernatants of bryo-1-stimulated crude BMNC fractions. Preincubation with TNF␣ did not result in an inhibitory effect on subsequent clonogenic capacity of either BMNC or CD34
+ cells ( Figure 5 ). On the contrary, higher TNF␣ doses even stimulated myeloid clonogenicity of crude BMNC as well as isolated CD34 + cells ( Figure 5 ). It might be argued that despite thorough washing, residual cell-bound bryostatin could continuously and now during the CFU assay stimulate accessory cells to produce TNF␣. This can be excluded since continuous incubation of CD34
+ cells with a wide dose range of TNF␣ concentrations, now present during the whole period of the CFU assay, did not result in clonogenic inhibition ( Figure 6 ).
To study whether TNF␣ can exert its inhibitory effect only in the presence of bryo-1 itself, we preincubated CD34
+ cells with 675 pg TNF␣ per ml together with 250 nM bryo-1. Clonogenicity was still 96 ± 8.4% of untreated control cells (data not shown), thereby excluding such a possibility.
These data show that for bryo-1-induced inhibition of hematopoietic progenitor cell growth apart from TNF␣, other factor(s) released from non-CD14 cells and all or not in combination with bryo-1 itself are necessary.
To study whether the release of such hypothetical secondary factor(s) could be caused by TNF␣, TNF␣ was added to CD14 + -depleted cultures. In these cultures the exogenously added TNF␣ could completely substitute for the inhibitory effect resulting from bryo-1-induced TNF␣ release from CD14 + cells in crude BMNC (as previously shown in Figure 3 ), but only if in addition to TNF␣, bryo-1 was present during the preincubation period ( Table 2) .
Role of bryo-1 in inhibition of myelopoiesis
To define the role of bryo-1 itself in the inhibitory effect on clonogenicity we used two approaches to avoid the presence of bryo-1. On the one hand, we dialysed bryo-1-conditioned medium over night by using a 3000 cut-off membrane. This treatment partially restored the clonogenic capacity after preincubation (Table 3 , second part). Addition of bryo-1 during the preincubation period again resulted in further inhibition, indicating that the effect was due to the diminishing concentrations of bryo-1.
On the other hand, we prepared TNF␣-conditioned medium (TNF-CM), because we had already shown a crucial role for TNF␣ in the induction of a second inhibitory factor.
Preincubation of CD34
+ cells in this TNF-CM did not reduce the clonogenic cell growth (Table 3 , third part). However, if bryo-1 was exogenously added, again inhibition of the clonogenicity was seen to the same extent as compared to the nondialysed bryo-1-CM (Table 3) . These results indicate that the presence of bryo-1 itself is necessary to provide a costimulatory signal together with the second factor, which in turn is produced in non-CD14 + cells upon stimulation by TNF␣, and probably together with TNF␣ itself, to exert an inhibitory effect on CD34
+ clonogenicity. (21) 19 (22) BMNC were depleted from CD14 + cells and stimulated for 24 h with 100 U/ml TNF␣ in the presence or absence of 250 nM bryo-1. After the incubation period the cells were plated in quadruplicate in a CFU-GM assay. Numbers of granulocytic colonies and clusters were evaluated and expressed as mean number per plated cells. As a reference, crude BMNC resulted in 87 and bryo-1-treated BMNC in 17 colonies and clusters. The effect of bryo-1 alone can be seen from Figure 3 . Table 3 Role of TNF␣-induced secondary factor and bryo-1 in inhibition of the clonogenic capacity of purified CD34
+ cells
Conditioned Dialysis of CM Bryo-1 added to CM CFU-GM per medium during incubation of culture
Conditioned medium (CM) was prepared by incubating MNC from bone marrow either with 250 nM bryo-1 (bryo-1-CM) or 100 U/ml TNF␣ (TNF␣-CM) for 24 h. The supernatants were harvested. One part was used for incubation of CD34 + cells for 24 h in the presence or absence of bryo-1. After washing, cells were plated in a CFU-GM assay and evaluated after 12 days. The other part was dialysed to remove bryo-1 and subsequently used in similar experiments as the non-dialysed part.
Effect of neutralizing bryo-1-conditioned media (CM) on clonogenicity
To determine the nature of the suppressive factor(s), conditioned medium (CM) obtained from BMNC precultures in the absence and presence of bryo-1 was tested. Measurement of TNF␣ concentrations revealed a basal TNF␣ level of 23 pg/ml in control CM (diluted 1:1) and 677 pg/ml TNF␣ in bryo-1-stimulated CM (1:1). This CM was preincubated with antibodies against IL4, IL8, IL10, MIP-1␣, TGF␤, or TNF␣. Subsequently, CD34
+ cells were preincubated in this 'neutralized' medium and clonogenic results were compared to CD34 + cells preincubated in control CM. In contrast to the effects of anti-TNF␣ in cultures in the presence of accessory cells, the addition of anti-TNF␣ to CM did not change the inhibitory effect of CM and CFU-GM remained inhibited (Figure 7) . Also the other antibodies were ineffective. These results show again that TNF␣ itself has no direct role in the inhibition of myelopoiesis but that the inhibition is the result of the combined presence of bryo-1 itself and a secondary factor induced by TNF␣ in non-CD14
+ cells, which in turn was released by bryo-1 exposure in CD14 + cells.
Figure 7
Effects of neutralizing cytokine antibodies in bryo-1-conditioned medium on inhibition of myelopoiesis. Purified CD34
+ bone marrow cells were preincubated for 24 h in conditioned medium (CM) from bryo-1-stimulated crude bone marrow mononuclear cells. Designated cytokines were neutralized in this CM by cytokine neutralizing antibodies. Results are presented as the percentage myeloid (CFU-GM) colony-forming cells ± s.e.m. compared to control cultured CD34 + cells. The number of experiments performed is shown in parentheses beside each cytokine. CFU-GM numbers per 10 3 plated CD34 + cells were 257 ± 38 (mean ± s.e.m.).
Discussion
The effects of bryostatins on normal and leukemic human bone marrow mononuclear cells (BMNC) are strongly dependent on dose and scheduling. Previous studies have shown that preincubation with 1-10 nM and sometimes even 250 nM of bryostatin exerted stimulatory effects on leukemic BMNC clonogenicity, whereas preincubation with 100-500 nM bryo-1 consistently inhibited subsequent BMNC colony formation of normal donors. 9 However, in our present study, normal purified CD34
+ cell clonogenicity was not affected by exposure to 250 nM bryo-1 suggesting that accessory cells produced an inhibitory factor towards clonogenic growth of CD34 + cells. This hypothesis was confirmed in co-cultivation experiments, in which accessory cells were kept separate from CD34 + cells by a semi-permeable membrane. Experiments with crude BMNC in the presence of a selected panel of antibodies capable of neutralizing cytokines inhibitory towards human hematopoietic clonogenicity, 10, 11 clearly identified TNF␣ as playing an essential role in mediating the effects of bryo-1. Cell depletion experiments identified CD14
+ cells as the source of TNF␣ secretion. Subsequently, it was demonstrated that bryo-1-stimulated BMNC culture supernatants contained increased concentrations of TNF␣ and that these supernatants inhibited purified CD34 + cells clonogenicity. Bryo-1 has been reported to induce TNF␣ secretion in several cell types. Lilly et al 12 demonstrated that the supernatants of four out of five chronic myelomonocytic leukemia (CMMoL) cell samples treated in vitro with bryo-1 contained increased TNF␣ concentrations. 12 In HL60 leukemia cells bryo-1 has been shown to increase TNF␣ mRNA transcription. 13 Recently, Steube and Drexler 14 reported that the human monocytic cell line MONO-MAC-6 rapidly released TNF␣ in response to bryo-1 stimulation. A phase I clinical study in humans with bryo-1 reported significant increases in the plasma concentration of TNF␣ after 2 h in 50% of the patients treated, 15 although another study could not substantiate this finding. 16 The pleiotropic cytokine TNF␣, which is produced by activated monocytes, macrophages and T cells, has been shown by several investigators to inhibit myeloid, as well as, erythroid progenitor cell growth, depending on concentration, duration of exposure, and the presence of other cytokines. [17] [18] [19] [20] Interestingly, in our study it could be demonstrated that TNF␣ by itself did not represent the inhibitory factor towards normal bone marrow progenitor cell clonogenicity since anti-TNF␣ was unable to restore clonogenic CD34 + cell inhibition induced by bryo-1-conditioned medium and TNF␣ over a wide dose range did not inhibit CD34 + cell clonogenicity. Moreover, the combination of TNF␣ and bryo-1 failed to inhibit purified CD34
+ cell clonogenicity indicating that other accessory cell-derived factor(s) were involved. CD14
+ cells are not the source of the inhibitory factor, since the addition of TNF␣ and bryo-1 to CD14 + -depleted BMNC still inhibited CFU-GM. The use of TNF␣-conditioned medium showed that one or more enigmatic factor(s) are secreted in response to TNF␣ priming of accessory cells. Furthermore, we have established that these factor(s) are functionally active only in the presence of bryo-1.
TNF␣ as well as bryo-1 affect PKC activity. It is known that bryostatins translocate and activate the various isotypes of PKC. PKC activity in its turn plays a key role in regulating cytokine receptor expression in different cell types, including AML samples. 21, 22 The induction of TNF receptors (TNFR1 or 2) can be achieved by inhibition of PKC by staurosporine. 23 Bryo might act in a similar way. Within 5 min of high doses of bryo-1 activation, PKC is redistributed from the cytosol to the membrane fractions. However, this stimulatory effect is lost about 4 h after bryo-1 exposure and within 24 h a nearly complete depletion of active PKC occurs. 24 Thus while bryostatins initially activate PKC, sustained activation and high doses of bryo lead to PKC downregulation. For the induction of the described inhibitory factor the upregulation of the TNFRs by bryo-1 is not needed because it also occurs in the absence of bryo-1. However, it cannot be excluded that TNF␣ produced upon bryo-1 addition upregulates its own receptors or that the costimulatory role of bryo-1 is based upon direct or indirect modulation of the receptor for the inhibitory cytokine.
Also, TNF␣ is known to interact with many growth factor receptors, such as the receptor for IL-3, GM-CSF, G-CSF and c-kit and thus could have an indirect effect on clonogenic growth. Although we did not measure the actual number of TNF␣ receptors in our culture system, no effect of TNF␣ concentrations was found at concentrations which included those found in culture supernatants upon bryo-1 exposure (up to 1 ng/ml; Figure 4 ) in the colony-forming assay. A higher dose of TNF (Ͼ3 ng) even stimulated CFU forming which is in line with reports from the literature when amounts of 10-20 ng/ml TNF are usually used in vitro. 18 Thus it seems unlikely that the inhibition of the clonogenic growth is regulated at the TNF␣-receptor level.
TNF␣ secretion leads to activation of homeostatic mechanisms trying to counteract effects of this cytokine. The most potent monocytic macrophage-deactivating cytokine induced by TNF␣ is IL-10, providing an efficient autocrine mechanism for controlling proinflammatory cytokine production in monocytes. 25, 26 Neutralization of IL-10 in bryo-1-conditioned medium, however, could not abolish the inhibitory effects observed. Additional neutralization experiments showed that neither IL4, IL8, MIP-1␣ nor TGF-␤ accounted for the inhibitory effect of bryo-1-conditioned medium towards myeloid clonogenicity.
The exact mechanism of bryo-1-induced inhibition of human bone marrow progenitor cell colony formation therefore remains to be characterized.
However, the involvement of cytokines in bryo-1-induced inhibition of hematopoietic progenitor cell growth may not be restricted to growth inhibitory cytokines. Synergistic suppression either by growth stimulatory cytokines or growth inhibitory cytokines could also lead to the effects observed. 27, 28 These experiments provide more insight into our previous study showing that acute myeloid leukemia (AML) blast cells, derived from patients, preincubated with 250 nM bryo-1 commonly showed an increased plating efficiency. Because TNF␣ is known to enhance leukemia cell growth, 29, 30 bryo-1-induced TNF␣ release from accessory cells might explain bryo-1-induced spurring of leukemia cell growth. Future studies with bryo-1 and anti-TNF␣ on AML cell growth should resolve this issue. In support of a putative differential role of TNF␣ in normal and leukemic hematopoiesis, Kobari et al 31 found leukemic blast cell-conditioned medium to contain increased amounts of TNF␣. In addition, this blast cellconditioned medium inhibited normal CFU-GM formation. Further studies on this issue may provide a more detailed understanding of autocrine or paracrine cytokine loops in AML.
The results from the present study are summarized in a hypothetical scheme shown in Figure 8 , demonstrating that
Figure 8
Hypothetical model: role of bryo-1 and TNF␣ in inhibition of myeloid clonogenic capacity. The inhibition of CD34
+ clonogenic cell growth is a multistep process, including the production of TNF␣ by CD14
+ cells upon bryo-1 stimulation (1) and the induction of an unknown soluble factor from non-CD14 + cells by TNF␣ (2), which in turn exerts its inhibitory effect only together with bryo-1 as a co-stimulant.
bryo-1 exerts a dual role in the inhibition of clonogenic cell growth. Firstly, upon bryostatin-1 stimulation normal CD14 + bone marrow cells secrete TNF␣ which plays a prime role in the inhibition of hematopoietic progenitor cell growth. Secondly, TNF␣ itself does not act as an inhibitory factor in our culture system towards progenitor cell growth, but induces an enigmatic second factor deriving mainly from non-CD14 accessory cells. This factor cannot be neutralized by antibodies directed against IL4, IL8, IL10, MIP-1␣ and TGF-␤. Thirdly, this factor together with bryo-1 itself is responsible for CD34 + colony growth inhibition. In addition, these results also show that biologic responses of human hematopoietic progenitor cells to bryostatin are not only dependent on the bryostatin concentration used 9 but also on the composition of the surrounding cells. As mentioned above, these findings may help to understand our previous studies describing heterogenous stimulatory and inhibiting effects of bryostatin on AML blast cell growth. 9 Further studies on the effects of bryostatin-1 on CD34
+ cells are required to gain more insight into cytokine loops and to better define inhibitory cytokines.
